ダウンロード数: 174

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
cbr.2022.0057.pdf1.57 MBAdobe PDF見る/開く
タイトル: Strategies for Preclinical Studies Evaluating the Biological Effects of an Accelerator-based BNCT System
著者: Kondo, Natsuko
Masutani, Mitsuko
Imamichi, Shoji
Matsumoto, Yoshitaka
Nakai, Kei
著者名の別形: 近藤, 夏子
キーワード: accelerator-based BNCT systems
BNCT
preclinical studies
radiation biology
発行日: Apr-2023
出版者: Mary Ann Liebert Inc
誌名: Cancer Biotherapy & Radiopharmaceuticals
巻: 38
号: 3
開始ページ: 173
終了ページ: 183
抄録: This review discusses the strategies of preclinical studies intended for accelerator-based (AB)-boron neutron capture therapy (BNCT) clinical trials, which were presented at the National Cancer Institute (NCI) Workshop on Neutron Capture Therapy held from April 20 to 22, 2022. Clinical studies of BNCT have been conducted worldwide using reactor neutron sources, with most targeting malignant brain tumors, melanoma, or head and neck cancer. Recently, small accelerator-based neutron sources that can be installed in hospitals have been developed. AB-BNCT clinical trials for recurrent malignant glioma, head and neck cancers, high-grade meningioma, melanoma, and angiosarcoma have all been conducted in Japan. The necessary methods, equipment, and facilities for preclinical studies to evaluate the biological effects of AB-BNCT systems in terms of safety and efficacy are described, with reference to two examples from Japan. The first is the National Cancer Center, which is equipped with a vertical downward neutron beam, and the other is the University of Tsukuba, which has a horizontal neutron beam. The preclinical studies discussed include cell-based assays to evaluate cytotoxicity and genotoxicity, in vivo cytotoxicity and efficacy of BNCT, and radioactivation measurements.
著作権等: This is the accepted version of the following article: [Natsuko Kondo, Mitsuko Masutani, Shoji Imamichi, Yoshitaka Matsumoto, and Kei Nakai. Strategies for Preclinical Studies Evaluating the Biological Effects of an Accelerator-Based Boron Neutron Capture Therapy System. Cancer Biotherapy and Radiopharmaceuticals 2023 38:3, 173-183.], which has now been formally published in final form at Cancer Biotherapy & Radiopharmaceuticals at https://doi.org/10.1089/cbr.2022.0057. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.
This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
URI: http://hdl.handle.net/2433/284181
DOI(出版社版): 10.1089/cbr.2022.0057
PubMed ID: 36154293
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。